


Taiwan firm develops nano-medication to inhibit HIV replication

15 July 2015 | News | By BioSpectrum Bureau

Taiwan firm develops nano-medication to inhibit HIV replication



Singapore: Lorati, a Taiwan-based biotechnology and skincare company, has developed nano-medication to inhibit HIV-1 viral replication.

Mr David Lo, CEO, Lorati commented, "nano-medication, based on bentonite, also known as God's dirt, is believed to be the last-ditch treatment for AIDS. Unbelievable improvement can be obtained within one month of treatment by nano-medication. After being treated by a couple of months, AIDS patients can even go back to HIV-1 status, meaning, number of CD4+ increases substantially".

According to a test report from The Johns Hopkins University School of Medicine, nano-medication can 100 percent inhibit replication of HIV-1 in vitro. "No existing drug and/or regiment of drugs for HIV-1/AIDS can achieve the same performance," said Mr Lo

Furthermore, it has been scientifically verified that nano-medication does not cause any side effects. Neither does it have drug resistance issue. "If AIDS patients want to be out of critical condition, nano-medication is the only resort," said Mr Lo.

Mr Lo explained, "Nano-medication can tackle HIV-1 both extracellularly and intracellularly." Nano-particles of nano-medication can bond to HIV-1 spikes, meaning glycoprotein 120 (gp120) and glycoprotein 41 (gp41), which are polar chemicals. Since gp120 contains 50 percent of glycans, it is extremely difficult for organic medicine to bond to it.

The company is now looking for strategic partners to conduct clinical trials on AIDS.